PT - JOURNAL ARTICLE AU - Brunmair, Julia AU - Bileck, Andrea AU - Schmidl, Doreen AU - Hagn, Gerhard AU - Meier-Menches, Samuel M. AU - Hommer, Nikolaus AU - Schlatter, Andreas AU - Gerner, Christopher AU - Garhöfer, Gerhard TI - Metabolic phenotyping of tear fluid as a prognostic tool for personalised medicine exemplified by T2DM patients AID - 10.1101/2021.11.30.21267045 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.30.21267045 4099 - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267045.short 4100 - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267045.full AB - Background/Aims One goal of predictive, preventive, and personalised medicine is to improve the prediction and diagnosis of diseases, as well as to monitor therapeutic efficacy and to tailor individualised treatments with as little side effects as possible. New methodological developments should preferably rely on non-invasively sampled biofluids like sweat and tears in order to provide optimal compliance. Here we have thus investigated the metabolic composition of human tears in comparison to finger sweat and evaluated whether tear analyses may provide insight into ocular and systemic disease mechanisms.Methods In addition to finger sweat, tear fluid was sampled from 20 healthy volunteers using commercially available Schirmer strips. Tear fluid extraction and analysis using high-resolution mass spectrometry hyphenated with liquid chromatography was performed with optimized methods each for metabolites and eicosanoids. As second approach, we performed a clinical pilot study with 8 diabetic patients and compared them to 19 healthy subjects.Results Tear fluid was found to be a rich source for metabolic phenotyping. Remarkably, several molecules previously identified by us in sweat were found significantly enriched in tear fluid, including creatine or taurine. Furthermore, other metabolites such as kahweol and various eicosanoids were exclusively detectable in tears, demonstrating the orthogonal power for biofluid analysis in order to gain information on individual health states. The clinical pilot study revealed that many endogenous metabolites that have previously been linked to type 2 diabetes such as carnitine, tyrosine, uric acid and valine were indeed found significantly up-regulated in tears of diabetic patients. Nicotinic acid and taurine were elevated in the diabetic cohort as well and may represent new biomarkers for diabetes specifically identified in tear fluid. Additionally, systemic medications like metformin, bisoprolol, and gabapentin, were readily detectable in tears of patients. These findings highlight the potential diagnostic and prognostic power of tear fluid analyses, in addition to the promising methodological support for pharmacokinetic studies and patient compliance control.Conclusions Tear fluid analysis may support the development of clinical applications in the context of predictive, preventive, and personalised medicine as it reveals rich molecular information in a non-invasive way.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Austrian Science Foundation (FWF Project No. KLI 721)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committee of the Medical University ViennaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is secured and available upon reasonable request to the authorsAbbreviationsAAarachidonic acidAspaspartateBMIbody mass indexDHAdocosahexaenoic acidEPAeicosapentaenoic acidGlnglutamineGluglutamateHbA1cglycated haemoglobinHETEhydroxyeicosatetraenoic acidLCliquid chromatographym/zmass-to-charge ratioMetmethionineMetOmethionine sulfoxideMSmass spectrometrynAUCnormalised area under the curvePCAprincipal component analysisPPPMpredictive preventive and personalised medicineROSreactive oxygen speciesRTretention timeSerserineT2DMtype 2 diabetes mellitusThrthreonineTNFαtumour necrosis factor alphaTyrtyrosineValvaline